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Abstract 
 Parkinson’s Disease (PD) is one of the most common 
neurodegenerative diseases. Several molecular mechanisms are involved. 
The objective of conducting this study was to evaluate the expression of 
iNOS in mouse experimental model of PD. PD was induced through 
injecting mice with 10 doses of MPTP (25 mg/kg) and probenecid (250 
mg/kg). Mice in control group were injected by saline (25 mg/kg). 
Immunohistochemical stains for iNOS in brain sections were carried out 
using indirect immunoperoxidase techniques. Study findings showed that 
there was a significant difference in the expression level iNOS in study 
groups (P<0.001), and experimental PD group had more expressed iNOS 
levels compared with control group. Taken together, the present study 
confirmed the impact of induction of iNOS in the etiology of PD.   
 
Keywords: 
 
Introduction 
 Parkinson’s disease (PD) is a chronic-progressive and disabling 
neurological disorder (Tolosa, 2006). From a pathologic point of view, PD 
can be defined by nigrostriatal loss of dopaminergic cells and Lewy bodies in 
the surviving cells on autopsy. Furthermore, PD may be manifested from a 
clinical point of view by a broad spectrum of motor and non-motor features. 
The four cardinal features of PD can be grouped under the acronym TRAP: 
tremor at rest, rigidity, akinesia (or bradykinesia) and postural instability. 
This syndrome is labeled “parkinsonism” and may also occur in other 
medical conditions than idiopathic PD, such as dementia with Lewy bodies, 
cerebrovascular disease, the so called parkinsonian plus syndromes or as side 
effect after administration of neuroleptic medication. The presence of 
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akinesia and one of the other symptoms are considered sufficient for the 
clinical diagnosis of parkinsonism. Diagnostic criteria have been developed 
by the UK Parkinson’s Disease Society Brain Bank and the National Institute 
of Neurological Disorders and Stroke (NINDS) (Tolosa, 2006). Other 
diagnostic criteria for clinical subgroups of the disease were suggested by 
Larsen et al (1994).  According to a study conducted by Jankovic (2008), 
flexed posture and motor blocks (freezing) have been included among classic 
features of PD. It has been shown that the diagnosis of PD is still based on 
the presence of a combination of cardinal motor features, associated and 
exclusionary symptoms, and response to levodopa (Rao, 2003).  
 Nitric oxide (NO) is gas in nature and it is produced by nitric oxide 
synthase (NOS) family of enzymes from L-arginine (Seet, 2010; Juurlink, 
1999). It is known as a highly reactive signaling molecule having a few 
seconds of life time (Juurlink, 1999). Furthermore, it diffuses with ease 
(Juurlink, 1999). Nitric oxide is  membrane permeable and can diffuse into 
dopaminergic neurons (Ara, 1998). Thus NO receptors are signaling 
transduction for intracellular communication. Once generated, the cell cannot 
control the local concentration of NO. Calabrese et al., shows that the 
activity of NO can be influenced by the degree of its synthesis and the 
activity is terminated with its reaction with its substrate (Seet, 2010). This is 
implicated in many physiological and pathological processes within the 
mammalian body (Moncada, 1997). 
 It has been shown that a histopathological evidence that NO and 
glutamate in toxic dose may mediate certain neurodegenerative diseases 
(Przedborski, 1996). Postmortem studies, clinical findings, and evidence 
from experimental models revealed the role of NO in the degeneration of 
dopaminergic neurons in PD. Studies performed in the MPTP model of PD 
suggest that peroxynitrite, a reactive species formed by the nearly diffusion-
limited reaction of nitric oxide with superoxide, may be a mediator of 
nigrostriatal damage in PD (Ara, 1998). Over limit NO could contribute to 
the formation of free radicals that could be involved in the death of 
dopaminergic neurons, resulting in development of PD symptoms (Tuncel, 
2009). Excess NO synthesis is likely to be involved in the progressive 
neuronal loss that distinguishes PD (Hancock, 2008). However, there is 
significant reduction in NO level in PD patients than in controls. The 
explanations for these low levels may be a faulty NO-dependent adaptation 
mechanism or the depletion of NO storage during the course of PD (Tuncel, 
2009).  
 Moreover, as cytokines enhance the induction of NOS in brain; many 
studies suggest the role of glial derived NO in the pathogenesis of these 
diseases. Some studies showed that there was excessive formation of NO of 
glial origin in which NADPH diaphorase (a cytochemical marker of NOS 
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activity) positive glial cells have been identified in the substantia nigra of 
postmortem brains obtained from individuals with Parkinson’s disease (Seet, 
2010). 
 Several animals and human studies showed that of the three isoforms, 
only the nNOS and iNOS are relevant with regard to their potential impact in 
neurodegeneration and glial response in PD (Kroncke, 1998). Several 
experiments showed that animals can be protected against MPTP by nNOS 
inhibitors (Seet, 2010; Kroncke, 1998). This gives evidence that the nNOS is 
responsible for MPTP neurotoxicity (Al-Jarrah, 2010). Furthermore, 
mutation in nNOS gene makes the mice more resistance to MPTP than wild-
type mice. Similar experiments with iNOS show that this enzyme also plays 
a role in the dopaminergic neurons sensitivity (Kroncke, 1998). In human, 
overproduction of NO was detected in the substantia nigra of PD brain. It 
was correlated with high concentration of nNOS and iNOS (Al-Jarraha, 
2010). Moreover, NOS inhibition protects against MPTP-induced loss of 
nigral neurons. Inhibition of NOS activity can stop MPTP-induced damage 
of dopaminergic nerve terminals in the striatum and the loss of dopaminergic 
cell bodies in the substantia nigra pars compacta  (Dishman, 2006).  
 
 Study objectives  
 The main objective of the current study is to study the expression of 
iNOS in mice experimental model of PD using immunohistochemical 
techniques. 
 
Methodology 
 Twenty Albino mice were selected randomly and assigned into 2 
groups: Control group (N=10), PD group (N=10).  
 The animals were housed in individual cages under identical 
conditions (22 ± 1 °C, free access to standard chow and water, 12 hours 
dark/light cycle). PD was induced by injecting mice with 10 doses of MPTP 
(25 mg/kg) and probenecid (250 mg/kg) (chemicals were obtained from 
Sigma Chemical Co. (St. Louis, MO, USA)). Mice in control group were 
injected by saline (25 mg/kg). 
 
iNOS immunostaining of brain tissue 
 The mice were sacrificed, and their brains were removed and fixed in 
10% formalin, embedded in paraffin, and sliced into 3 micometer thick 
sections. Then, the 3 μm thick sections were processed via 
immunohistochemistry using an antibody to iNOS (Santa Cruz 
biotechnology). So, the 3 micron thick paraffin-embedded sections mounted 
on glass slides were deparaffinized in xylene for 2 minutes twice, and 
subsequently rehydrated through serially descending dilutions of alcohol 
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(starting with 100%, and ended with 70%) followed by water (2 minutes for 
each step). After that, sections were processed for antigen retrieval in the 
reveal solution (RV 1000M, Biocare Medical, Concord, CA) under pressure 
in the Decloaking chamber (Biocare medical) for 2 minutes. Tissue sections 
were then cooled down to room temperature, and incubated with 3% 
hydrogen peroxidase in methanol for 5 minutes. After washing the sections 
in phosphate buffered saline (PBS), they were incubated with iNOS antibody 
(Santa Cruz Biotechnology), with the dilution recommended by the vendor, 
at room temperature for one hour. Next, the sections were washed in PBS 
and treated with secondary antibodies and Streptavidin using  
ImmunoCruz™ goat ABC Staining System (sc-2023). Diaminobenzidine 
(DAB) was applied for 2 minutes or longer, until the desired intensity was 
developed, and then the slides were washed with tap water to stop the 
reaction. Negative control sections were processed without the primary 
antibody. All sections were then counterstained with hematoxylin and 
viewed under the light microscope. Ten slides of brain tissues from each 
animal group were evaluated for iNOS expression by 
immunohistochemistry. 
 
Data analysis 
 The sections were photographed with digital camera. Photoshop 
software was used. The slides from each group were analyzed by counting 
the total pixels area occupied by positive staining. iNOS expression was 
analyzed, in the different brain tissues, and statistically compared among the 
2 different groups using paired student t-test. Differences in iNOS expression 
were considered statistically significant at P value < 0.05. 
 
Results  
The expression of iNOS in study groups 
 The study findings showed that the expression level of iNOS in 
control group was 0.125 and this expression level was further increased in 
Parkinson’s disease group, 0.21 (Figure 1). This variation in the expression 
level in study groups was statistically significant (P< 0.001) .  
 
Figure 1: comparison of expression level of iNOS among study groups 
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Discussion  
 The present study was conducted to evaluate the expression level of 
iNOS in PD compared with control group.  
 The results of the present study clearly identified a significant 
involvement of iNOS in the etiology of PD. This finding agrees with other 
studies in which it was found that iNOS has impacts in neurodegeneration 
and glial response in PD and plays a role in the dopaminergic neurons 
sensitivity (Kroncke, 1998).  
 The increase of iNOS is possibly due to the release of cytokines and 
other immunity mediators, which induce iNOS. Moreover, Husain and 
Hazelrigg (2002) found that the exercise training and chronic NOS inhibitor 
(nitro-L-arginine methyl ester, LNAME) administration lead to a significant 
induction of iNOS after exercise in heart of rats. This may be due to increase 
blood flow during exercise which leads to the upregulation of iNOS, or may 
be due to positive effect of exercise on catecholamines, and hence 
upregulation of iNOS expression.  
 In human, overproduction of NO was detected in the substantia nigra 
of PD brain. It was correlated with high concentration of nNOS and iNOS 
(Al-Jarraha, 2010). Moreover, NOS inhibition protects against MPTP-
induced loss of nigral neurons. Inhibition of NOS activity can stop MPTP-
induced damage of dopaminergic nerve terminals in the striatum and the loss 
of dopaminergic cell bodies in the substantia nigra pars compacta  (Dishman, 
2006).  
 
Conclusion  
 The present study confirmed the impact of induction of iNOS in the 
etiology of PD. 
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